Clinical trial
Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease
NCT03671889 is registered in ClinicalTrials.gov with InSightec as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease
- Lead sponsor
- InSightec
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- September 28, 2018
- Completion date
- January 31, 2030
- Enrollment
- 50 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.